US Edition
Published • loading... • Updated
According to an Analysis, Prices for New Drugs Are Too High Across Europe.
Summary by Deutsches Ärzteblatt
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Berlin – According to a recent study by the Association Internationale de la Mutualité (AIM), whose members include the Association of Substitute Health Insurance Funds (vdek), prices for new, patented drugs are too high across Europe. The study indicates that up to €27 billion could be lost annually in all EU member states due to the high prices of new drugs...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
